Taffix® blocks the Omicron Variant of SARS-CoV-2 in addition to the Alpha (UK) and Beta (South African) and Delta Variants Tel Aviv , Israel January 19 2022 – Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public...
